AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 10864113
Drug: Hot, humid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hot, humid air inhaled in a chamber
Trial: 3878719
Drug: Propofol (with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propofol (with lignocaine 0.5 mg)
Trial: 28704328
Drug: Dexamethasone (DXM)
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Dexamethasone (DXM) alone (20 mg IV)
Trial: 28704328
Drug: Dexamethasone (DXM)
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Dexamethasone (DXM) plus Hydrocortisone (HCT) (100 mg IV)
Trial: 25341431
Drug: Electroacupuncture (EA)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Electroacupuncture (EA) treatment, 30-min weekly for 3 weeks
Trial: 16391584
Drug: 15 microg
RxNorm normalized name: Tafluprost 15 microgram/mL eye drops
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15 microg (600 IU) vitamin D(3) and 1,500 mg calcium/day for 8 weeks
Trial: 16391584
Drug: 1,500 mg
RxNorm normalized name: garlic 1,500 mg ORAL CAPSULE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1,500 mg calcium/day for 8 weeks (control group)
Trial: 15292721
Drug: Acupressure on
RxNorm normalized name: Gel-One
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acupressure on P6 point (Nei-Guan) for 5 minutes at least 3 times a day before chemotherapy and mealtimes
Trial: 15292721
Drug: Regular antiemesis
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Regular antiemesis medication (Control group)
Trial: 11441413
Drug: 100 mg/m2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg/m2 docetaxel for three cycles before definitive surgery or radiotherapy
Trial: 11441413
Drug: Neoadjuvant docetaxel
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Neoadjuvant docetaxel in combination with cisplatin or carboplatin
Trial: 9158047
Drug: Pentoxifylline (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pentoxifylline (20 mg/kg/day intravenously in 150 ml of saline for five days)
Trial: 9158047
Drug: Placebo (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (150 ml of saline without POF)
Trial: 8198036
Drug: Enalapril 20
RxNorm normalized name: enalapril 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enalapril 20 mg plus hydrochlorothiazide 12.5 mg (group 2)
Trial: 8198036
Drug: Enalapril 20
RxNorm normalized name: enalapril 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enalapril 20 mg (group 1)
Trial: 2195345
Drug: Topical cyclosporine
RxNorm normalized name: Cyclosporine
DrugBank: Cyclosporine (DB00091)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical cyclosporine (100 mg/ml, 5 ml, three times daily)
Trial: 31919134
Drug: Neoadjuvant chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neoadjuvant chemotherapy (taxane and anthracycline)
Trial: 31919134
Drug: Residual cancer
RxNorm normalized name: antihemophilic factor, human recombinant residues 743-1636 deleted Injection [Xyntha]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Residual cancer after neoadjuvant chemotherapy
Trial: 30850828
Drug: Basal diet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Basal diet + 100 mg MEF/kg diet
Trial: 30850828
Drug: Basal diet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Basal diet + 300 mg ECOS/kg diet
Trial: 30850828
Drug: Basal diet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Basal diet + 100 mg MEF/kg diet + 300 mg ECOS/kg diet
Trial: 30850828
Drug: Basal diet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Basal diet + 500 mg ECOS/kg diet
Trial: 30850828
Drug: Basal diet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Basal diet + 100 mg MEF/kg diet + 500 mg ECOS/kg diet
Trial: 28052513
Drug: Problem Solving
RxNorm normalized name: Solv X
DrugBank: Salicylic acid (DB00936)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Problem Solving Therapy (PST, n = 10)
Trial: 21707926
Drug: Gepirone-ER (40-80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gepirone-ER (40-80 mg/day)
Trial: 19486255
Drug: TACE-IFN (interferon-alpha1b
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TACE-IFN (interferon-alpha1b at a dose of 3 million units three times a week for 48 weeks)
Trial: 11579890
Drug: Atovaquone-proguanil (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atovaquone-proguanil (1 tablet daily for 7 days)
Trial: 7880659
Drug: Clonidine 5
RxNorm normalized name: apraclonidine 5 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clonidine 5 micrograms kg‐1 and famotidine 20 mg (n = 20)
Trial: 7880659
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (famotidine 20 mg) (n = 20)
Trial: 2835200
Drug: Conventional prazosin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional prazosin (2 mg)
Trial: 2835200
Drug: Oros prazosin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oros prazosin (5.5 mg)
Trial: 29909377
Drug: Aspirin (81
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin (81 or 100 mg daily)
Trial: 27041480
Drug: Candesartan at
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Candesartan at a dose of 16 mg per day plus hydrochlorothiazide at a dose of 12.5 mg per day
Trial: 23735519
Drug: Amantadine hydrochloride
RxNorm normalized name: Amantadine Hydrochloride
DrugBank: Amantadine (DB00915)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Amantadine hydrochloride (200 to 400mg daily for 4 weeks)
Trial: 23735519
Drug: Placebo (daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (daily for 4 weeks)
Trial: 18670333
Drug: Cervical medial
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cervical medial branch blocks with bupivacaine and steroid (steroid group)
Trial: 12941993
Drug: Low-dose combined
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose combined angiotensin-converting enzyme inhibitor and calcium channel blocker antihypertensive treatment
Trial: 12941993
Drug: Two preselected,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two preselected, fixed-dose combination therapies
Trial: 9215092
Drug: Aciclovir 200
RxNorm normalized name: Aciclovir 200 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aciclovir 200 mg five times daily
Trial: 8203335
Drug: Enalapril 5
RxNorm normalized name: enalapril 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enalapril 5 mg three times daily
Trial: 3311120
Drug: Codeine (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Codeine (30 mg four times daily)
Trial: 3311120
Drug: Promethazine (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Promethazine (25 mg four times daily)
Trial: 25864939
Drug: Fluoxetine (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluoxetine (20 mg single dose)
Trial: 21266929
Drug: Caffeine (6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caffeine (6 mg·kg(‐1))
Trial: 9624028
Drug: Short-acting antibiotics
RxNorm normalized name: Short-acting sulfonamides
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Short-acting antibiotics for 5 days
Trial: 9624028
Drug: Short-acting antibiotics
RxNorm normalized name: Short-acting sulfonamides
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Short-acting antibiotics for 8 to 10 days
Trial: 9624028
Drug: Long course
RxNorm normalized name: long pepper extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Long course of short-acting antibiotics
Trial: 9624028
Drug: Short-acting antibiotics
RxNorm normalized name: Short-acting sulfonamides
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Short-acting antibiotics
Trial: 7911624
Drug: Triamcinolone acetonide
RxNorm normalized name: Triamcinolone Acetonide
DrugBank: Triamcinolone (DB00620)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Triamcinolone acetonide monotherapy
Trial: 7911624
Drug: Hydrocolloid dressing
RxNorm normalized name: hydrocolloid dressing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydrocolloid dressing monotherapy
Trial: 31536837
Drug: 1 g
RxNorm normalized name: Molds 1 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 g of TXA for every 1000 mL of the distending medium
Trial: 31536837
Drug: 10 mL
RxNorm normalized name: Vial Empty 10 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mL of placebo (10 mL of 1.5% glycine) in the same form inside every 1000 mL of the distention medium
Trial: 31557812
Drug: Polar M400
RxNorm normalized name: Polar Freeze
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Polar M400 use and twice‐weekly social cognitive theory‐ and self‐determination theory‐based Facebook‐delivered health education intervention
Trial: 29101095
Drug: Smartphone CBT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Smartphone CBT app (Kokoro-app) in addition to medication change
Trial: 21991727
Drug: 2 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mg/kg tramadol (group T, n = 35)
Trial: 21991727
Drug: 1 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg/kg lidocaine 2% (group L, n = 35)
Trial: 11322206
Drug: 10 MU
RxNorm normalized name: saliva substitute comb no.10 MUCOUS MEM POWDER IN PACKET (EA)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 MU IFN daily
Trial: 11322206
Drug: 5 MU
RxNorm normalized name: MULTISTIX 5 MULTIPLE TEST STRIP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 MU twice-daily
Trial: 8646870
Drug: Betamethasone valerate
RxNorm normalized name: Betamethasone Valerate
DrugBank: Betamethasone (DB00443)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Betamethasone valerate cream, 0.1%
Trial: 2258448
Drug: Fenfluramine 40‐120
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fenfluramine 40‐120 mg/day
Trial: 498825
Drug: Terbutaline 2.5
RxNorm normalized name: terbutaline 2.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Terbutaline 2.5 mg
Trial: 7416558
Drug: Theophylline 130
RxNorm normalized name: theophylline 130 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Theophylline 130 mg
Trial: 7416558
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of Theophylline 130 mg and Terbutaline 2.5 mg
Trial: 28382660
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (medical treatment and routine care only, without intervention)
Trial: 18614727
Drug: Bolus tube
RxNorm normalized name: Sus scrofa fallopian tube preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bolus tube feeding (6.93 ± 0.38 MJ/d of 4.18 kJ/mL multinutrient feed)
Trial: 12108334
Drug: Intravenous interleukin-2
RxNorm normalized name: Interleukin-2 aldesleukin
DrugBank: Aldesleukin (DB00041)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous interleukin-2
Trial: 12108334
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of interleukin-2 and interferon
Trial: 8646822
Drug: Erythromycin (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Erythromycin (400 mg orally three times a day for 10 days)
Trial: 1475039
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg pyritinol dihydrochloride-monohydrate, 3 times daily for 12 weeks
Trial: 6706234
Drug: Adjuvant therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant therapy (various modalities)
Trial: 6706234
Drug: No further
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No further treatment after primary surgery
Trial: 25427553
Drug: Conservative treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conservative treatment without reduction of the fracture
Trial: 18763027
Drug: acitretin 0.4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: acitretin 0.4 mg/kg per day
Trial: 17367446
Drug: Parenteral testosterone
RxNorm normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Parenteral testosterone (Sustanon 250 intramuscular injection)
Trial: 17367446
Drug: Letrozole 2.5
RxNorm normalized name: letrozole 2.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Letrozole 2.5 mg orally daily
Trial: 8229622
Drug: Control oral
RxNorm normalized name: Dayquil Mucus Control Oral Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control oral hygiene methods
Trial: 26463007
Drug: L-epinephrine plus
RxNorm normalized name: Epinephrine
DrugBank: Epinephrine (DB00668)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: L-epinephrine plus dexamethasone
Trial: 14568987
Drug: High-dose etoposide,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose etoposide, ifosfamide, and cisplatin (VIP) chemotherapy plus autologous stem cell support, administered in one cycle followed by three to four sequential cycles every 3 weeks.
Trial: 14568987
Drug: High-dose VIP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose VIP chemotherapy with stem cell support.
Trial: 14568987
Drug: Dose level
RxNorm normalized name: peanut allergenic extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose level 6 of high-dose VIP (cisplatin 100 mg/m2, etoposide 1500 mg/m2, ifosfamide 10 g/m2) recommended for further investigation.
Trial: 1455371
Drug: Hemosorption weekly
RxNorm normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Hemosorption weekly for 3 weeks, followed by cyclophosphamide 1000 mg IV after the second procedure, then methotrexate 7.5 mg weekly.
Trial: 1455371
Drug: Methotrexate 7.5
RxNorm normalized name: methotrexate 7.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methotrexate 7.5 mg weekly.
Trial: 1455371
Drug: Cyclophosphamide 200
RxNorm normalized name: cyclophosphamide 2000 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyclophosphamide 200 mg IV twice a week for 6 times, then 200 mg weekly orally until a total dose of 2 g.
Trial: 1455371
Drug: Azathioprine 100
RxNorm normalized name: azathioprine 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Azathioprine 100 mg daily.
Trial: 3334188
Drug: Ranitidine at
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ranitidine at 300 mg daily for the control of symptoms of non-ulcer dyspepsia
Trial: 29746903
Drug: famciclovir 500mg
RxNorm normalized name: FAMCICLOVIR 500MG TAB
DrugBank: Famciclovir (DB00426)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: famciclovir 500mg (one tablet) three times daily for 7 days
Trial: 29746903
Drug: acyclovir 800mg
RxNorm normalized name: ACYCLOVIR 800MG TAB
DrugBank: Acyclovir (DB00787)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: acyclovir 800mg (two capsules) five times daily for 7 days
Trial: 27354043
Drug: Long-acting nifedipine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Long-acting nifedipine (10-60 mg/day)
Trial: 24355438
Drug: Protein pulse
RxNorm normalized name: protein C
DrugBank: Protein C (DB11312)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Protein pulse feeding (PD), 72% of dietary protein consumed in one meal at noon, averaging 1.31 g/kg body weight daily
Trial: 24355438
Drug: Protein spread
RxNorm normalized name: protein C
DrugBank: Protein C (DB11312)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Protein spread feeding (SD), dietary protein spread over four daily meals
Trial: 21502597
Drug: Huperzine A
RxNorm normalized name: Huperzine A
DrugBank: Huperzine A (DB04864)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Huperzine A 200 μg BID
Trial: 21502597
Drug: Huperzine A
RxNorm normalized name: Huperzine A
DrugBank: Huperzine A (DB04864)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Huperzine A 400 μg BID
Trial: 16766774
Drug: Special nutritional
RxNorm normalized name: Ocean Blue Nutritionals Omega-3 1450 Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Special nutritional supplement providing 90 mg isoflavones, 800 mg calcium, 400 IU vitamin D, 60 ug vitamin K and 31 g proteins per day.
Trial: 16766774
Drug: Usual nutritional
RxNorm normalized name: Ocean Blue Nutritionals Omega-3 1450 Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Usual nutritional supplement provided by the Chilean Ministry of Health.
Trial: 11115724
Drug: Rhesus rotavirus-based
RxNorm normalized name: rotavirus vaccine, live attenuated, G1P[8] human 89-12 strain Oral Suspension [Rotarix]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rhesus rotavirus-based quadrivalent vaccine
Trial: 9543218
Drug: 1000 mg
RxNorm normalized name: bran 1000 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1000 mg of micronised flavonoid fraction for 2 months
Trial: 19734790
Drug: gabapentin 1200
RxNorm normalized name: Gabapentin
DrugBank: Gabapentin (DB00996)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: gabapentin 1200 mg + dexamethasone 8 mg + ketamine (0.15 mg kg(‐1)) + paracetamol 1 g + ketorolac 15 mg
Trial: 19734790
Drug: placebo +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo + paracetamol 1 g + ketorolac 15 mg
Trial: 18364384
Drug: Diet and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diet and exercise (treatment group; n = 17)
Trial: 18364384
Drug: No therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No therapy (control group; n = 10)
Trial: 15452357
Drug: Cream adjusted
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cream adjusted to pH 4.0
Trial: 15452357
Drug: Cream adjusted
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cream adjusted to pH 7.5
Trial: 12417880
Drug: Fluticasone propionate
RxNorm normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Fluticasone propionate (FP) 150 microg twice daily, n = 20
Trial: 7532559
Drug: Methylene blue
RxNorm normalized name: Methylene Blue
DrugBank: Methylene blue (DB09241)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methylene blue (2 mg/kg)
Trial: 6123021
Drug: Synthetic methionyl
RxNorm normalized name: Synthetic camphor
DrugBank: Synthetic camphor (DB14156)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Synthetic methionyl human growth hormone
Trial: 6123021
Drug: Pituitary human
RxNorm normalized name: posterior pituitary hormones
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pituitary human growth hormone
Trial: 19067286
Drug: IV ibuprofen
RxNorm normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: IV ibuprofen (10 mg/kg, 5 mg/kg, and 5 mg/kg over 3 days)
Trial: 16112120
Drug: Vegetable lipid
RxNorm normalized name: guggul lipids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vegetable lipid intake >or=34.4 g/day
Trial: 16112120
Drug: Vitamin E
RxNorm normalized name: Vitamin E
DrugBank: Vitamin E (DB00163)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Vitamin E intake >or=7.726 mg/day
Trial: 11775393
Drug: Budesonide inhalation
RxNorm normalized name: Budesonide Inhalation Powder
DrugBank: Budesonide (DB01222)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Budesonide inhalation suspension (BIS; Pulmicort Respules)
Trial: 10518847
Drug: Conventional asthma
RxNorm normalized name: epinephrine
DrugBank: Epinephrine (DB00668)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Conventional asthma therapy (CAT)
Trial: 31759183
Drug: MGO Manuka
RxNorm normalized name: manuka oil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MGO Manuka Honey microemulsion eye cream applied to one eye overnight for 3 months
Trial: 31759183
Drug: MGO Manuka
RxNorm normalized name: manuka oil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MGO Manuka Honey microemulsion eye cream
Trial: 25740268
Drug: Pradigastat 40
RxNorm normalized name: Pradigastat
DrugBank: Pradigastat (DB12866)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pradigastat 40 mg with a single dose of Levora‐28®
Trial: 24122191
Drug: Hyperbaric oxygen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hyperbaric oxygen treatment (HBOT) administered within 24 h to 48 h of burn injury
Trial: 18984264
Drug: Oral montelukast
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral montelukast for 8 weeks in addition to oral prednisolone for 14 days and budenoside nasal spray for 8 weeks
Trial: 18984264
Drug: Oral prednisolone
RxNorm normalized name: prednisolone Oral Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral prednisolone for 14 days and budenoside nasal spray for 8 weeks (Control)
Trial: 15465071
Drug: GAD patients
RxNorm normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GAD patients (preanxiolytic treatment)
Trial: 15465071
Drug: Anxiolytic-treated GAD
RxNorm normalized name: trimethylsilyl treated diimethiconol-trimethylsiloxysilicate crosspolymer (45-55 WW)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anxiolytic-treated GAD patients
Trial: 15465071
Drug: GAD patients
RxNorm normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GAD patients after treatment
Trial: 11465435
Drug: Autologous blood
RxNorm normalized name: Banked autologous blood
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Autologous blood transfusion with intravenous injection of erythropoietin 600 lU/kg after each blood predonation
Trial: 9509446
Drug: Haemodialysis for
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Haemodialysis for 3 hours started after contrast medium administration
Trial: 8044451
Drug: Tiagabine (32
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tiagabine (32 mg during open phase, 24 mg during double-blind phase)
Trial: 3056807
Drug: Biosynthetic human
RxNorm normalized name: Proinsulin biosynthetic human
DrugBank: Proinsulin human (DB17875)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Biosynthetic human insulin (0.025, 0.05, 0.1 units/kg)